Ribavirin

Breastfeeding
  • TRADE NAMES: Copegus (Roche); Rebetol (Schering-Plough); Rebetron (Schering); Viramid; Virazid; Virazole (Valeant)
  • INDICATIONS: Respiratory syncytial viral infections
  • CLASS: Antiviral; nucleoside analog
  • HALF-LIFE: 24 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Abacavir, Azathioprine, Didanosine, Emtricitabine, Interferon Alfa, PEG-Interferon, Stavudine, Zidovudine

PREGNANCY CATEGORY: X

[INH] = Inhalation; [O] = Oral.

Rebetron is ribavirin and interferon.

RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS

See full prescribing information for complete boxed warning.

Our database has 154 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 02/01/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top